Uveitis reactivation following recombinant zoster vaccination

Paige J Richards; Maxwell J Wingelaar; Karen R Armbrust; Laura J Kopplin

doi:10.1016/j.ajoc.2021.101115

Uveitis reactivation following recombinant zoster vaccination

Am J Ophthalmol Case Rep. 2021 May 3:23:101115. doi: 10.1016/j.ajoc.2021.101115. eCollection 2021 Sep.

Authors

Paige J Richards¹, Maxwell J Wingelaar¹, Karen R Armbrust^{2

3}, Laura J Kopplin¹

Affiliations

¹ University of Wisconsin Department of Ophthalmology and Visual Sciences, United States.
² University of Minnesota, Department of Ophthalmology and Visual Neurosciences, United States.
³ Minneapolis Veterans Affairs Health Care System, Department of Ophthalmology, United States.

Abstract

Purpose: Describe three cases of uveitis reactivation following immunization with recombinant zoster vaccine (RZV).

Observations: One patient developed reactivation of previously controlled multifocal choroiditis within one week of receiving RZV, requiring treatment with systemic corticosteroids. Two patients with previously controlled anterior uveitis developed new anterior segment inflammation after RZV; both were treated with topical corticosteroids and systemic antiviral therapy.

Conclusion and importance: Uveitis recurrence is an infrequent but serious potential ocular side effect of recombinant zoster vaccination.

Keywords: Autoimmune; Multifocal choroiditis; Shingrix; Uveitis; Vaccine.

Publication types

Case Reports